JNJ Stock Recent News
JNJ LATEST HEADLINES
Axsome Therapeutics has multiple catalysts on the way. Johnson & Johnson is a bargain with its improving growth prospects.
Milvexian is a drug candidate under development by Bristol Myers and Johnson & Johnson. In a phase 2 clinical trial, milvexian produced encouraging results in preventing strokes.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson is spinning off its consumer health business this year as it pivots more toward its pharmaceutical and medtech businesses. Kellogg will spin off its North American cereal business, allowing it to focus more on snacks, which have generated better growth for it in recent years.
Blue chip stocks might give you a better balance of risk to potential reward than other investments. Taking advantage of catch-up contributions will let you put more into your retirement plans.
Johnson & Johnson has increased annual revenue for seven consecutive years. The company is pointing to revenue growth between 4.5% and 5.5% this year.
There's a lot of uncertainty in the market these days. Companies with strong financial profiles will be able to endure these challenging times.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team.
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Now more than ever, investors are looking for high-quality companies to invest in. There were some rumblings that we're in a new bull market, but the latest developments have been concerning.